Showing 2161-2170 of 2494 results for "".
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- BioTissue to Present Research Into the Application of Cryopreserved Amniotic Membrane (CAM) at ASCRShttps://modernod.com/news/biotissue-to-present-research-into-the-application-of-cryopreserved-amniotic-membrane-cam-at-ascrs/2482201/Ophthalmologists at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston will be sharing research that offers new insights into the application of Cryopreserved Amniotic Membrane (CAM). Among these advancements is the utilization of Bio
- CorNeat EverPatch Synthetic Tissue Substitute Now Available in the UShttps://modernod.com/news/corneat-everpatch-synthetic-tissue-substitute-now-available-in-the-us/2482138/CorNeat Vision announced the commerical launch of the CorNeat EverPatch, a synthetic tissue-integrating matrix for ocular surface surgeries. The EverPatch, which received FDA 510(k) clearance in June 2023, offers a combination of features that provide an advantage over ex
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- Regenxbio Announces Interim Data from Phase 2 AAVIATE Trial of ABBV-RGX-314 for Wet AMD Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-interim-data-from-phase-2-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery/2482066/Regenxbio announced positive interim data from the phase 2 AAVIATE trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) using suprachoroidal delivery. Investigational ABBV-RGX-314 is designed to be a one-time, in office treatment that has the potent
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo